Risen Pharma, a clinical-stage innovative drug R&D group with international competitiveness, announced that it has signed a licensing agreement with Taikang Biopharma Co., Ltd. (hereinafter referred to as "Taikang Biopharma"), a wholly-owned subsidiary of Maiwei Bio (688062.SH), for the group's research and development project RP901. According to the agreement, Risen Pharma grants Taikang Biopharma the rights to research, develop (including through contract research organizations), register, commercialize, and sell the RP901 project and accompanying diagnostics (developed solely for the purpose of using the licensed product) within the Greater China region, including Mainland China, Hong Kong, Macau, and Taiwan; Risen Pharma is responsible for pharmaceutical research and production within the Greater China region and retains the rights to the project outside of the Greater China region. As per the terms of the agreement, Risen Pharma will receive an upfront payment and milestone payments totaling over 1.1 billion RMB, as well as a royalty fee of up to double-digit percentages of net sales.